Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

11335

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Live official records

Open in full search

Conditions: Metastatic Breast Cancer
Interventions: Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more

Conditions: Stroke, Transient Ischemic Attack
Interventions: TargEted MAnageMent Intervention (TEAM); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 159
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo matching BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 1,755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 38
States / cities: San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more

Conditions: Proteinuric Kidney Diseases
Interventions: BI 764198, Placebo matching BI 764198; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Huntsville, Alabama • Glendale, California • Granada Hills, California + 20 more

Conditions: Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions: Anifrolumab, Anifrolumab; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Parkinson Disease
Interventions: AP-472, Placebo; Drug · Other
Lead sponsor: Appello Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more

Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Carvedilol, Laboratory Biomarker Analysis, Patient Observation; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 577
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more

Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions: KPL-387, Placebo; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Live official records

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Reducing Stroke Risk in African-American Men

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387